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The study by Schlecht et al1 of adolescent girls and young women answers 4 important questions.
First, do sexually active adolescent girls and young women have detectable oral human
papillomavirus (HPV)? Second, if so, how long does it take for oral HPV to be cleared? Third, is oral
HPV associated with HPV in other anatomic sites? Fourth, in this population, is vaccination with the
quadrivalent HPV vaccine associated with reduced prevalence of oral HPV? The authors found that,
yes, the study participants who attended an urban, free adolescent clinic had oral HPV, because 6.2%
of their oral rinses hadHPV types that can causemucosal infections. Second, the participants overall
quickly cleared their incident oral HPV. Third, detectable cervical HPVwas associated with oral HPV,
linking HPV at the cervix as an indicator of future detection of HPV in the oral cavity. Fourth, and
most significant, if the participants had received at least 1 dose of the quadrivalent HPV vaccine, they
had a lower risk of oral HPV than those whowere fully unvaccinated.
These findings are important to examinemore closely. The oral HPV prevalence rate reported
by Schlecht et al1 matches recent data for oral rinses in adults2 and demonstrates that their
participants’ exposure rates to HPVwere typical of large clinical cohorts, and not unique to a single
urban clinic site. Also, when incident detection of oral HPV did occur, the participants were able to
clear it quickly. Almost none had oral HPV that remained for more than 12months, and this trend also
prevailed longitudinally. When determined according to years since first sexual activity, the longer a
participant had been sexually active, the lower her odds of having oral HPV detected.
With regard to the data on vaccine efficacy in this cohort,1 the association was strong. There
have beenmultiple studies3,4 in adolescents who received the 3-dose HPV vaccine that demonstrate
high-titer antibody responses to the HPV types included in the vaccine3 and clinical protection
against infection at anogenital sites.4 However, to our knowledge, no other study to date has looked
at the association between vaccination and clinical protection against HPV infection the oral cavity,
specifically in minority girls and young women. This makes the findings of Schlecht et al1 even more
critical. Participants in this studywhowere vaccinated had fewer episodes of incident oral HPVDNA.
Adding to the robustness of this finding is that these data extend fromparticipants whomirror
an intention-to-treat, rather than a per-protocol, cohort in clinical trials. First, participants were not
excluded if they had not completed the full 3-dose series (which was the standard recommendation
when theywere enrolled). Instead, Schlecht et al1 considered their participants as vaccinated if they
had received at least 1 dose. Recent research5 has shown that 2 doses, or even 1, of the HPV vaccine
canmount type-specific titers to HPV and are associatedwith a decreased risk of HPV infection and
disease. The study by Schlecht et al1 expands that association to oral HPV protection as well. Second,
participants were not excluded if they had not received their vaccine series before becoming sexually
active. The data demonstrating protection from oral HPVmay be evenmore robust among
adolescents who received 1 or more vaccination dose before exposure through sexual activity, and it
would be very interesting to determine whether those who had oral HPV detected had been
vaccinated before they became sexually active.
Schlecht et al1 did an excellent job collecting sexual histories from their participants. Knowing
where anatomically someone has been exposed to HPV, and the timing of that exposure, is critical to
understanding the natural history and clearance rates of an infection. It is also important to
understand whether HPV infections in 1 anatomic site can be associated with infection at other sites.
+ Related article
Author affiliations and article information are
listed at the end of this article.
Open Access. This is an open access article distributed under the terms of the CC-BY License.
JAMA Network Open. 2019;2(10):e1914038. doi:10.1001/jamanetworkopen.2019.14038 (Reprinted) October 25, 2019 1/3
Downloaded From: https://jamanetwork.com/ by a Indiana University School of Medicine User  on 08/07/2020
Other studies6-8 have shown these links between cervical and anal infections and disease, and now
the study by Schlecht et al1 associates cervical HPV detection with oral HPV detection, although not
yet with disease.
Few prevalence or prevention data on oral HPV have been collected amongminority
adolescents, especially those who live in urban areas, making the study by Schlecht et al1 very
important. However, there are limitations that should be noted. First, the study was conducted at a
single clinical site. Future studies at multiple sites, and among different socioeconomic cohorts of
participants, will add robustness to the data on oral HPV. Second, nearly all participants in the study
had received at least 1 dose of the quadrivalent HPV vaccine. Only 15% had not. This is laudable for
the clinic, having been able to administer the HPV vaccine to a cohort thatmanywould consider to be
high risk behaviorally and socioeconomically. However, the comparison group of participants,
nonvaccinated vs vaccinated, is not equal in size, and the size discrepancy also limits the power to
detect important risk factors for HPV acquisition. In addition, there may be some associated risk
factor amongminority adolescents and young adults who attend a free clinic, and yet do not receive
an offered vaccine, that leads to increased oral HPV prevalence. This should be further studied.
The most important limitation in this study’s findings is that it is of girls and women only. The
risk of HPV-associated head and neck squamous cell carcinoma is much higher among men than
among women; some estimates are that, for every woman, 2 to 5men receive a diagnosis.9,10 With
that inmind, we do not know the oral incidence, prevalence, and clearance of HPV in adolescent boys
and youngmen in general, let alone those who are part of aminority group. The National Health and
Nutrition Examination Survey data2 show greater HPV DNA prevalence amongmen vs women, and
this increases with the number of lifetime partners. Do men have a greater risk of oral HPV
acquisition or a poorer clearance of infection? Is exposure greater for a manwho has sex with women
vs a man who has sex with men?Males may be a challenging group to study, but these are critical
questions that currently remain unanswered. The data presented in the study by Schlecht et al,1
however, lay the groundwork to study HPV in males and, if similar findings are noted, provide yet
another reason to vaccinate adolescent boys and youngmen against HPV.
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